公开(公告)号：US11732286B2

公开(公告)日：2023-08-22

申请号：US17670738

申请日：2022-02-14

Applicant: Fenfei Leng ,  Zifang Deng

Inventor： Fenfei Leng ,  Zifang Deng

IPC: C12Q1/68 ,  C07H21/00 ,  C12Q1/533 ,  C12Q1/44 ,  G01N21/64

CPC classification number: C12Q1/533 ,  C12Q1/44 ,  G01N21/6428 ,  G01N2021/6439 ,  G01N2500/04 ,  G01N2500/20

Abstract: The present invention provides assays and methods for studying DNA topology and topoisomerases. The assays and methods utilize a circular plasmid DNA comprising one or more hairpin structures and the ability of T5 exonuclease (T5E) to digest the circular plasmid DNA in a specific configuration. The assays and methods can be used as a high throughput screening for inhibitors of, for example, DNA gyrases and DNA topoisomerases I for anticancer drug and antibiotics discovery.

公开(公告)号：US20180296554A1

公开(公告)日：2018-10-18

申请号：US15949703

申请日：2018-04-10

Applicant: UNIVERSITY OF SOUTH FLORIDA

Inventor： JONATHAN JACOB SABBAGH ,  CHAD DICKEY

IPC: A61K31/496 ,  A61K45/06 ,  A61K31/454 ,  A61K31/46 ,  A61K31/42 ,  A61K31/15 ,  A61K31/137 ,  A61K31/4168 ,  A61K31/5415 ,  C12Q1/533 ,  A61K31/36 ,  A61K31/138 ,  A61K31/135

CPC classification number: A61K31/496 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/15 ,  A61K31/36 ,  A61K31/4168 ,  A61K31/42 ,  A61K31/454 ,  A61K31/46 ,  A61K31/5415 ,  A61K45/06 ,  C12Q1/533 ,  G01N2333/99 ,  A61K2300/00

Abstract: The subject invention concerns materials and methods for treating depression, stress disorders, such as PTSD, anxiety disorders, and/or a neurodegenerative disease or condition in a person or animal. In one embodiment, a person or animal in need of treatment is administered one or more compounds or drugs, or a composition comprising the one or more compounds or drugs, that inhibit FKBP51 activity or function. The subject invention also concerns a method for inhibiting activity of the FKBP51 protein in a cell. The subject invention also concerns methods of screening for compounds or drugs that inhibit the FKBP51 protein.

公开(公告)号：US10000807B2

公开(公告)日：2018-06-19

申请号：US15254553

申请日：2016-09-01

Applicant: Fenfei Leng ,  Xiaoduo Zhi ,  Samantha Dages ,  Kelley Dages

Inventor： Fenfei Leng ,  Xiaoduo Zhi ,  Samantha Dages ,  Kelley Dages

IPC: C12Q1/6876 ,  C12N15/70 ,  C12N9/90 ,  C12Q1/66 ,  C12Q1/68

CPC classification number: C12Q1/6876 ,  C12N9/90 ,  C12N15/1086 ,  C12N15/63 ,  C12N15/70 ,  C12Q1/025 ,  C12Q1/533 ,  C12Q1/66 ,  C12Q2600/158 ,  C12Y599/01003 ,  G01N33/5023

Abstract: The disclosure describes the effects of transcription mediated from a promoter on the transcription mediated by divergently coupled supercoiling-sensitive promoter. Transcription initiated from a promoter inhibits transcription mediated by a specific supercoiling-sensitive promoter that is divergently coupled to the promoter. A gyrase inhibitor relieves this inhibition and substantially increases the transcription mediated by the specific supercoiling-sensitive promoter that is divergently coupled to another promoter. Accordingly, the invention pertains to a method for identifying a compound as a gyrase inhibitor or not a gyrase inhibitor based on differential expression of genes under the control of divergently coupled promoters in the presence of the compound. Another embodiment of the invention provides an assay for identifying one or more compounds from a library of compounds as a gyrase inhibitor. Polynucleotides and cells containing such polynucleotides that are suitable for carrying out the methods described herein are also provided.

公开(公告)号：US20170137895A1

公开(公告)日：2017-05-18

申请号：US15311006

申请日：2015-05-15

Applicant: ZYMONOSTICS APS

Inventor： Magnus Stougaard ,  Birgitta Ruth Knudsen ,  Marianne Smedegaard Hede ,  Jonas Thomsen ,  Yi-Ping Ho

IPC: C12Q1/68 ,  C12Q1/48 ,  C12Q1/533

CPC classification number: C12Q1/6893 ,  C12Q1/025 ,  C12Q1/04 ,  C12Q1/25 ,  C12Q1/485 ,  C12Q1/533 ,  C12Q1/68 ,  C12Q1/689 ,  G01N33/573 ,  G01N2333/9015 ,  G01N2333/91245 ,  G01N2800/26 ,  Y02A50/58 ,  C12Q2521/501 ,  C12Q2533/107 ,  C12Q2565/629 ,  C12Q2521/507 ,  C12Q2521/519

Abstract: The invention provides a method of identifying a microorganism that expresses a nucleic acid-modifying enzyme, in sample, the method comprising: (a) contacting a nucleic acid substrate targeted by the nucleic acid-modifying enzyme with the sample; (b) adding a further nucleic acid molecule to the sample which nucleic acid molecule is ligated to the nucleic acid substrate in the presence of the nucleic acid-modifying enzyme to form a ligation product which comprises a linear single strand of nucleic acid that is capable of being detected; and (c) detecting the presence of the ligation product.

公开(公告)号：US09487818B2

公开(公告)日：2016-11-08

申请号：US13825750

申请日：2011-09-22

Applicant: Somasundaram Kumaravel ,  Arivazhagan Arimappamagan ,  Kandavel Thennarasu ,  Alangar Sathyaranjandas Hegde ,  Ashwathnarayana Chandramouli ,  Santosh Vani ,  Paturu Kondaiah ,  Satyanarayana Rao Manchanahalli Rangaswamy

Inventor： Somasundaram Kumaravel ,  Arivazhagan Arimappamagan ,  Kandavel Thennarasu ,  Alangar Sathyaranjandas Hegde ,  Ashwathnarayana Chandramouli ,  Santosh Vani ,  Paturu Kondaiah ,  Satyanarayana Rao Manchanahalli Rangaswamy

IPC: C12Q1/533 ,  A61K31/495 ,  G01N33/574

CPC classification number: C12Q1/533 ,  A61K31/495 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57407 ,  G01N2333/99 ,  G01N2800/52

Abstract: The present invention provides a TOP2A inhibition by temozolomide useful for predicting glioblastoma patient's survival. Glioblastoma (GBM) is the most common, malignant primary adult brain tumor. The conventional treatments for GBM, include surgery, radiation, and chemotherapy which have only modestly improved patient survival. The patients with GBM expressing higher TOP2A transcript levels had better prognosis. More interestingly, the present invention reports that temozolomide is an inhibitor of TOP2A activity in vitro. The present invention further shows that siRNA knock down of TOP2A rendered a glioma cell line resistant to temozolomide chemotherapy. Thus it is demonstrated for the first time that temozolomide is a TOP2A inhibitor and establishes that TOP2A transcript levels determines the chemosensitivity of glioblastoma to temozolomide therapy thus explaining the very high levels of TOP2A transcript being a good prognostic indicator in GBM patients receiving temozolomide chemotherapy.

Abstract translation: 本发明提供了可用于预测胶质母细胞瘤患者生存的替莫唑胺的TOP2A抑制。 成胶质细胞瘤（GBM）是最常见的恶性原发性成人脑肿瘤。 GBM的常规治疗方法包括手术，放射和化疗，只能适度改善患者的生存。 具有较高TOP2A转录水平的GBM患者预后较好。 更有趣的是，本发明报道了替莫唑胺是体外TOP2A活性的抑制剂。 本发明进一步显示，TOP2A的siRNA敲低使得对替莫唑胺化疗有抗性的胶质瘤细胞系。 因此，第一次证明替莫唑胺是TOP2A抑制剂，并且确定TOP2A转录物水平决定了胶质母细胞瘤对替莫唑胺治疗的化学敏感性，从而解释了非常高水平的TOP2A转录物是接受替莫唑胺化疗的GBM患者中良好的预后指标。

公开(公告)号：US20160090585A1

公开(公告)日：2016-03-31

申请号：US14853240

申请日：2015-09-14

Applicant: BASF ENZYMES LLC

Inventor： David P. WEINER ,  Ellen G. BURKE ,  Peter LUGINBUHL ,  Analia BUENO ,  Joslin M. CUENCA ,  Mervyn L. DE SOUZA ,  Sherry KOLLMANN

IPC: C12N9/90 ,  A61K38/52

CPC classification number: C12N9/90 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/10 ,  A23G3/366 ,  A23G4/123 ,  A23G4/14 ,  A23K20/189 ,  A23L29/06 ,  A23V2002/00 ,  A61K38/00 ,  A61K38/52 ,  C12Q1/533 ,  C12Y501/00 ,  C12Y501/01

Abstract: This invention relates generally to enzymes, polynucleotides encoding the enzymes, the use of such polynucleotides and polypeptides and more specifically to enzymes having isomerase activity, e.g., racemase activity, e.g., amino acid racemase activity, alanine racemase activity, and/or epimerase activity, and/or catalyze the re-arrangement of atoms within a molecule, catalyze the conversion of one isomer into another, catalyze the conversion of an optically active substrate into a raceme, which is optically inactive, catalyze the interconversion of substrate enantiomers, catalyze the stereochemical inversion around the asymmetric carbon atom in a substrate having only one center of asymmetry, catalyze the stereochemical inversion of the configuration around an asymmetric carbon atom in a substrate having more than one asymmetric center, and/or catalyze the racemization of amino acids. Thus, the invention provides enzymes, compositions, methods for production of pharmaceutical compositions, pharmaceutical intermediates, antibiotics, sweeteners, peptide enzymes, peptide hormones, fuel and fuel additive compositions, foods and food additives, beverage and beverage additives, feeds and feed additives, drugs and drug additives, dietary supplements, textiles, wood, paper, pulp, and detergents comprising the polypeptides or polynucleotides in accordance with the invention.

Abstract translation: 本发明一般涉及酶，编码酶的多核苷酸，这种多核苷酸和多肽的用途，更具体地涉及具有异构酶活性的酶，例如消旋酶活性，例如氨基酸消旋酶活性，丙氨酸消旋酶活性和/或差向异构酶活性， 和/或催化分子内原子的重新排列，催化一种异构体转化为另一种异构体，催化光学活性底物转化为光学无活性的外消旋体，催化底物对映异构体的相互转化，催化立体化学 在仅具有一个不对称中心的底物中的不对称碳原子周围反转，催化具有多于一个不对称中心的底物中不对称碳原子周围的构型的立体化学反转，和/或催化氨基酸的外消旋化。 因此，本发明提供了用于生产药物组合物，药物中间体，抗生素，甜味剂，肽酶，肽激素，燃料和燃料添加剂组合物，食品和食品添加剂，饮料和饮料添加剂，饲料和饲料添加剂的酶，组合物， 药物和药物添加剂，膳食补充剂，纺织品，木材，纸，纸浆和洗涤剂，其包含根据本发明的多肽或多核苷酸。

公开(公告)号：US20140287403A1

公开(公告)日：2014-09-25

申请号：US14350451

申请日：2012-10-12

Applicant: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)

Inventor： Sandor Kasas ,  Giovanni Longo ,  Giovanni Dietler ,  Livan Bladimir Alonso Sarduy

IPC: C12Q1/18 ,  C12Q1/533 ,  C12Q1/02

CPC classification number: C12Q1/18 ,  B82Y5/00 ,  B82Y35/00 ,  C12Q1/02 ,  C12Q1/533 ,  G01N29/036 ,  G01N29/2418 ,  G01N29/46 ,  G01N2291/0427

Abstract: Motion detector comprising a flexible support (1,5) adapted to hold at least one object (6-9), a sensor (4) for measuring the displacement of said support (1) and processing means for differentiating the fluctuations of said support (1) from those induced by said object (6-9).

Abstract translation: 运动检测器，包括适于保持至少一个物体（6-9）的柔性支撑件（1,5），用于测量所述支撑件（1）的位移的传感器（4）和用于区分所述支撑件 1）由所述物体（6-9）诱导的物体。

公开(公告)号：US20130143201A1

公开(公告)日：2013-06-06

申请号：US12458629

申请日：2009-07-17

Applicant: Paola Minoprio ,  Pedro Alzari ,  Alejandro Buschiazzo ,  Christophe Grégoire ,  Armand Berneman ,  Wim M. Degrave

Inventor： Paola Minoprio ,  Pedro Alzari ,  Alejandro Buschiazzo ,  Christophe Grégoire ,  Armand Berneman ,  Wim M. Degrave

IPC: C12N9/90

CPC classification number: C12N9/90 ,  C12N9/88 ,  C12Q1/533 ,  C30B7/00 ,  G01N33/573 ,  G01N2333/44 ,  Y02A90/26

Abstract: A method of identifying a substance that affects the biological activity of a Trypanosome cruzi proline racemase (TcPRAC) protein comprises providing a purified TcPRAC protein, providing a substance to be tested, combining the TcPRAC protein with the substance, and determining the effect of the substance on the biological activity of the TcPRAC protein.

Abstract translation: 识别影响锥虫脯氨酸消旋酶（TcPRAC）蛋白质生物活性的物质的方法包括提供纯化的TcPRAC蛋白，提供待测物质，将TcPRAC蛋白与物质结合，并确定物质的作用 关于TcPRAC蛋白的生物活性。

公开(公告)号：US20110136140A1

公开(公告)日：2011-06-09

申请号：US13055320

申请日：2009-07-21

Applicant: Péter Németh ,  Tamás Czömpöly ,  Tímea Berki ,  László Czirják

Inventor： Péter Németh ,  Tamás Czömpöly ,  Tímea Berki ,  László Czirják

IPC: G01N33/53 ,  C12N9/90

CPC classification number: G01N33/564 ,  C12Q1/533 ,  G01N2333/99 ,  G01N2800/104

Abstract: It has been found that the pattern of recognized topo I epitopes is different between dcSSc, IcSSc and SLE patients. Fragment F4 (amino acid (AA) 450-600) was recognized by all patients tested. Fragment F1 (AA 5-30) and Fragment F8 (AA 350-400) represent characteristic epitopes for dcSSc and SLE, respectively. The invention relates to diagnostic uses and methods as well as kits for use in diagnosis.

Abstract translation: 已经发现，识别的topo I表位的图案在dcSSc，IcSSc和SLE患者之间是不同的。 片段F4（氨基酸（AA）450-600）被所有测试的患者认可。 片段F1（AA 5-30）和片段F8（AA350-400）分别表示dcSSc和SLE的特征表位。 本发明涉及诊断用途和方法以及用于诊断的试剂盒。

公开(公告)号：US20110053245A1

公开(公告)日：2011-03-03

申请号：US12810067

申请日：2008-12-22

Applicant: David P. Weiner ,  Peter Luginbuhl ,  Analia Bueno ,  Joslin M. Cuenca ,  Mervyn L. De Souza ,  Sherry Kollmann

Inventor： David P. Weiner ,  Peter Luginbuhl ,  Analia Bueno ,  Joslin M. Cuenca ,  Mervyn L. De Souza ,  Sherry Kollmann

IPC: C12N9/90 ,  C12N15/52 ,  C12N15/80 ,  C12N15/81 ,  C12N15/82 ,  C12N15/85 ,  C12P21/02 ,  C12P19/34 ,  A23L1/172 ,  D21C3/20 ,  C12N9/42 ,  C12N9/48 ,  C12N9/24 ,  C12N9/08 ,  C12N9/10 ,  C12N9/16 ,  C12N9/88

CPC classification number: C12N9/90 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/10 ,  A23G3/366 ,  A23G4/123 ,  A23G4/14 ,  A23K20/189 ,  A23L29/06 ,  A23V2002/00 ,  A61K38/00 ,  A61K38/52 ,  C12Q1/533 ,  C12Y501/00 ,  C12Y501/01

Abstract: This invention relates generally to enzymes, polynucleotides encoding the enzymes, the use of such polynucleotides and polypeptides and more specifically to enzymes having isomerase activity, e.g., racemase activity, e.g., amino acid racemase activity, alanine racemase activity, and/or epimerase activity, and/or catalyze the re-, arrangement of atoms within a molecule, catalyze the conversion of one isomer into another, catalyze the conversion of an optically active substrate into a raceme, which is optically inactive, catalyze the interconversion of substrate enantiomers, catalyze the stereochemical inversion around the asymmetric carbon atom in a substrate having only one center of asymmetry, catalyze the stereochemical inversion of the configuration around an asymmetric carbon atom in a substrate having more than one asymmetric center, and/or catalyze the racemization of amino acids. Thus, the invention provides enzymes, compositions, methods for production of pharmaceutical compositions, pharmaceutical intermerdiates, antibiotics, sweeteners, peptide enzymes, peptide hormones, fuel and fuel additive compositions, foods and food additives, beverage and beverage additives, feeds and feed additives, drugs and drug additives, dietary supplements, textiles, wood, paper, pulp, and detergents comprising the polypeptides or polynucleotides in accordance with the invention.

Abstract translation: 本发明一般涉及酶，编码酶的多核苷酸，这种多核苷酸和多肽的用途，更具体地涉及具有异构酶活性的酶，例如消旋酶活性，例如氨基酸消旋酶活性，丙氨酸消旋酶活性和/或差向异构酶活性， 和/或催化原子在分子内的重新排列，催化一种异构体转化为另一种异构体，催化光学活性底物转化为光学无活性的外消旋体，催化底物对映异构体的相互转化，催化 仅具有一个不对称中心的基底中的不对称碳原子周围的立体化学反转，催化具有多于一个不对称中心的底物中不对称碳原子周围的构型的立体化学反转，和/或催化氨基酸的外消旋化。 因此，本发明提供了酶，组合物，药物组合物的制备方法，药物中间体，抗生素，甜味剂，肽酶，肽激素，燃料和燃料添加剂组合物，食品和食品添加剂，饮料和饮料添加剂，饲料和饲料添加剂， 药物和药物添加剂，膳食补充剂，纺织品，木材，纸，纸浆和洗涤剂，其包含根据本发明的多肽或多核苷酸。